By Lauren Gardner

Panel members voted 17-0 to recommend the shot, with one abstention.

The advisory committee endorsed the FDA’s decision to authorize a Moderna booster for people 65 and older and for all adults who either have underlying conditions or work in high-risk settings.

The advisory committee endorsed the FDA’s decision to authorize a Moderna booster for people 65 and older and for all adults who either have underlying conditions or work in high-risk settings.

The advisory committee endorsed the FDA’s decision to authorize a Moderna booster for people 65 and older and for all adults who either have underlying conditions or work in high-risk settings.

The advisory committee endorsed the FDA’s decision to authorize a Moderna booster for people 65 and older and for all adults who either have underlying conditions or work in high-risk settings.

The announcement clears the way for a major expansion of the country’s booster campaign.

The advisory committee endorsed the FDA’s decision to authorize a Moderna booster for people 65 and older and for all adults who either have underlying conditions or work in high-risk settings.

The announcement clears the way for a major expansion of the country’s booster campaign.

The U.S. government has twice tried to classify kratom as a controlled substance, but public outcry and pushback from Congress thwarted those efforts.

The U.S. government has twice tried to classify kratom as a controlled substance, but public outcry and pushback from Congress thwarted those efforts.

The U.S. government has twice tried to classify kratom as a controlled substance, but public outcry and pushback from Congress thwarted those efforts.

The U.S. government has twice tried to classify kratom as a controlled substance, but public outcry and pushback from Congress thwarted those efforts.

J&J said Monday that giving a second dose two months after the first increased protection against symptomatic moderate to severe Covid-19 to 94 percent, with 100 percent protection against severe illness.

J&J said Monday that giving a second dose two months after the first increased protection against symptomatic moderate to severe Covid-19 to 94 percent, with 100 percent protection against severe illness.

The final step in the process will come when CDC Director Rochelle Walensky approves the CDC advisory panel’s recommendations.

The final step in the process will come when CDC Director Rochelle Walensky approves the CDC advisory panel’s recommendations.

The CDC’s vaccine advisers will refine exactly who is eligible — in this case, that will likely involve defining “high risk.

The final step in the process will come when CDC Director Rochelle Walensky approves the CDC advisory panel’s recommendations.

The CDC’s vaccine advisers will refine exactly who is eligible — in this case, that will likely involve defining “high risk.

“For several weeks now, states have had to operate without clear guidance from the federal government regarding these booster shots,” Maryland Gov. Larry Hogan said.

The panel unexpectedly broke with the Biden administration’s push for a widespread booster campaign this fall.

The panel unexpectedly broke with the Biden administration’s push for a widespread booster campaign this fall.

The agency said observational studies don’t unanimously support the suggestion that the shot’s efficacy declines over time.

The agency said observational studies don’t unanimously support the suggestion that the shot’s efficacy declines over time.

A new research paper deals a blow to the FDA and to the Biden administration.

A new research paper deals a blow to the FDA and to the Biden administration.

Politicians have joined anxious parents and some public health groups in calling on federal regulators to accelerate their process for authorizing shots for the youngest Americans.

Politicians have joined anxious parents and some public health groups in calling on federal regulators to accelerate their process for authorizing shots for the youngest Americans.

Regulators are now left to chart a path forward despite limited, and sometimes confusing, data on vaccines’ effectiveness over time.

Regulators are now left to chart a path forward despite limited, and sometimes confusing, data on vaccines’ effectiveness over time.